LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P6959

    Prothionamide

    Nicotinic acid derivative; InhA inhibitor.

    ≥98%
  • G3553

    Ginsenoside Rb2

    Triterpene saponin found in species of Panax.

    ≥98%
  • L9600

    LY-2090314

    GSK-3 inhibitor.

    ≥98%
  • T1677

    Tetracycline

    Polyketide; protein translation inhibitor, mamm...

    ≥90%
  • T7032

    Triamcinolone

    Synthetic steroid; glucocorticoid agonist.

    ≥98%
  • E6257

    Epothilone B

    Microtubule depolymerization inhibitor.

    ≥98%
  • C1869

    Cerulenin

    Found in Cephalosporium; fatty acid synthase in...

    ≥98%
  • V3327

    Virginiamycin Mixture

    Macrolide antibiotic

    ≥97%
  • A5228

    Angiogenin

    Small protein, cleaves RNA.

    ≥98%
  • D5897

    Doxycycline Hyclate

    Tetracycline; protein translation inhibitor, MM...

    ≥97%
  • D1720

    Deferiprone

    Iron chelator.

    ≥99%
  • M3232

    Methylisoindigotin

    Indirubin derivative.

    ≥98%
  • N5778

    Notoginsenoside R1

    Triterpene saponin found in species of Panax.

    ≥98%
  • L0076

    Latrunculin A

    Thiazolidine macrolide found in the Red Sea spo...
  • B1878

    Betamethasone 21-Phosphate Sodium

    Steroid; glucocorticoid agonist.

    ≥98%
  • A9818

    Azelastine Hydrochloride

    TRPV1 agonist, histamine H1 antagonist.

    ≥98%
  • B8075

    4-tert-Butyl-5-Methoxy-1,2-quinone

    BHA derivative.

    ≥95%
  • M5753

    Monensin Sodium

    Polyether ionophore, autophagy inhibitor.

    ≥98%
  • S0278

    Satraplatin

    Pt-based DNA cross-linker.

    ≥98%
  • S5869

    Sorafenib Tosylate

    c-Raf, RET, VEGFR1 inhibitor, potential HMT inh...

    ≥99%